{"id":"peg-g-csf","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Bone pain"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-10","effect":"Splenomegaly"},{"rate":"<1","effect":"Splenic rupture"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"G-CSF binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and mobilization into peripheral blood. The pegylation (attachment of polyethylene glycol) extends the drug's half-life, allowing for less frequent dosing compared to non-pegylated G-CSF. This reduces the incidence of febrile neutropenia and associated infections in cancer patients receiving myelosuppressive chemotherapy.","oneSentence":"PEG-G-CSF is a pegylated granulocyte colony-stimulating factor that stimulates the bone marrow to produce and release neutrophils, reducing the duration and severity of chemotherapy-induced neutropenia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:09.795Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia in patients with non-myeloid malignancies"},{"name":"Reduction of duration of severe neutropenia in patients receiving myeloablative chemotherapy followed by bone marrow transplantation"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT04684368","phase":"PHASE2","title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-07-13","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma","enrollment":160},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT05296317","phase":"NA","title":"Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration","status":"COMPLETED","sponsor":"Centre Georges Francois Leclerc","startDate":"2022-09-02","conditions":"Localized Breast Cancer","enrollment":97},{"nctId":"NCT04685616","phase":"PHASE3","title":"Brentuximab Vedotin in Early Stage Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University College, London","startDate":"2022-04-14","conditions":"Hodgkin Lymphoma","enrollment":1042},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia","enrollment":42},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma","enrollment":50},{"nctId":"NCT05211336","phase":"PHASE1","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-04-19","conditions":"Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS","enrollment":14},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","enrollment":78},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":"Rhabdomyosarcoma","enrollment":115},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":"Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type","enrollment":20},{"nctId":"NCT03907488","phase":"PHASE3","title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-29","conditions":"Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma","enrollment":994},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT07188090","phase":"PHASE2","title":"Mozobil for Autologous Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-10-16","conditions":"Multiple Myeloma, Hodgkin Lymphoma, Non-hodgkin Lymphoma","enrollment":100},{"nctId":"NCT06711523","phase":"PHASE3","title":"Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kexing Biopharm Co., Ltd.","startDate":"2025-01-09","conditions":"Neutropenia, Chemotherapy-Induced Febrile, Breast Neoplasm Female","enrollment":250},{"nctId":"NCT05645718","phase":"PHASE2","title":"Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-07-14","conditions":"Leukemia","enrollment":27},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT05573386","phase":"","title":"Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim","status":"COMPLETED","sponsor":"Andrews Research & Education Foundation","startDate":"2021-08-09","conditions":"Healthy","enrollment":15},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT03220022","phase":"PHASE1","title":"Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-16","conditions":"AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","enrollment":46},{"nctId":"NCT06958614","phase":"","title":"Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2019-09-02","conditions":"Stage II-III Non-small Cell Lung Cancer, Concurrent Chemotherapy, Conditions Influencing Health Status","enrollment":213},{"nctId":"NCT03844360","phase":"PHASE4","title":"Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease","status":"RECRUITING","sponsor":"Wei Zhao","startDate":"2016-01-31","conditions":"Hematological Neoplasms","enrollment":1500},{"nctId":"NCT04023669","phase":"PHASE1","title":"Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-08-08","conditions":"Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory","enrollment":21},{"nctId":"NCT06520176","phase":"PHASE3","title":"Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08","conditions":"Multiple Myeloma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT00557193","phase":"PHASE3","title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01-15","conditions":"Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia","enrollment":218},{"nctId":"NCT01783535","phase":"PHASE2","title":"Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-19","conditions":"Retinoblastoma","enrollment":174},{"nctId":"NCT00381680","phase":"PHASE3","title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":"B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia","enrollment":275},{"nctId":"NCT05536154","phase":"NA","title":"Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2022-11-01","conditions":"Lymphoma, Multiple Myeloma","enrollment":68},{"nctId":"NCT06309732","phase":"PHASE2","title":"GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2006-07","conditions":"Testicular Neoplasms","enrollment":36},{"nctId":"NCT02013167","phase":"PHASE3","title":"Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-01-03","conditions":"Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","enrollment":405},{"nctId":"NCT00304070","phase":"PHASE3","title":"Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-05-03","conditions":"Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7","enrollment":78},{"nctId":"NCT02543255","phase":"PHASE2","title":"Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-09","conditions":"Prostate Cancer","enrollment":76},{"nctId":"NCT05970185","phase":"EARLY_PHASE1","title":"The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilization","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2024-02-01","conditions":"Granulocyte Colony-Stimulating Factor","enrollment":40},{"nctId":"NCT03858166","phase":"PHASE4","title":"Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer","status":"TERMINATED","sponsor":"Shandong University","startDate":"2017-12-01","conditions":"Adjuvant Chemotherapy, Ovarian Neoplasms, Ovarian Cancer","enrollment":68},{"nctId":"NCT06188676","phase":"PHASE3","title":"Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL","status":"RECRUITING","sponsor":"National Research Center for Hematology, Russia","startDate":"2022-04-01","conditions":"Primary Mediastinal Lymphoma","enrollment":100},{"nctId":"NCT06168188","phase":"EARLY_PHASE1","title":"The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2020-07-24","conditions":"Traumatic Optic Neuropathy","enrollment":20},{"nctId":"NCT02649673","phase":"PHASE1","title":"LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2016-03-23","conditions":"Small Cell Lung Cancer, Ovarian Cancer","enrollment":34},{"nctId":"NCT05510089","phase":"NA","title":"Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies","status":"UNKNOWN","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2022-09-01","conditions":"Hematological Malignancy","enrollment":62},{"nctId":"NCT06060080","phase":"NA","title":"Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma","status":"UNKNOWN","sponsor":"Yao Liu","startDate":"2022-04-22","conditions":"Lymphoma, Multiple Myeloma","enrollment":7},{"nctId":"NCT06026995","phase":"PHASE4","title":"Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells","status":"UNKNOWN","sponsor":"Chongqing University Cancer Hospital","startDate":"2022-03-01","conditions":"Lymphoma","enrollment":174},{"nctId":"NCT04542356","phase":"PHASE2","title":"Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer","status":"COMPLETED","sponsor":"Chongqing University Cancer Hospital","startDate":"2018-08-01","conditions":"Cervical Cancer","enrollment":60},{"nctId":"NCT05834751","phase":"NA","title":"the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma","status":"UNKNOWN","sponsor":"Ou Bai, MD/PHD","startDate":"2023-05-01","conditions":"Lymphoma","enrollment":144},{"nctId":"NCT01256398","phase":"PHASE2","title":"Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12-14","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":66},{"nctId":"NCT04477616","phase":"PHASE2","title":"Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-07-13","conditions":"Breast Cancer","enrollment":160},{"nctId":"NCT02511132","phase":"PHASE2","title":"A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma","status":"COMPLETED","sponsor":"Gradalis, Inc.","startDate":"2016-02-10","conditions":"Ewing's Sarcoma","enrollment":22},{"nctId":"NCT04554056","phase":"PHASE2, PHASE3","title":"Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF","status":"COMPLETED","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2020-09-21","conditions":"Breast Cancer Female","enrollment":586},{"nctId":"NCT01057069","phase":"PHASE2, PHASE3","title":"Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2010-01","conditions":"Breast Cancer","enrollment":310},{"nctId":"NCT05531279","phase":"NA","title":"A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-06-05","conditions":"Severe Aplastic Anemia","enrollment":45},{"nctId":"NCT04460508","phase":"PHASE2","title":"Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2020-12-20","conditions":"Chemotherapy-induced Neutropenia, Lymphoma","enrollment":170},{"nctId":"NCT05409547","phase":"PHASE4","title":"A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF","status":"UNKNOWN","sponsor":"Ning Huang","startDate":"2022-06-30","conditions":"Granulocyte Colony-stimulating Factor, Stem Cell Mobilization","enrollment":80},{"nctId":"NCT04466137","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2020-10-16","conditions":"Non-Myeloid Malignancy","enrollment":398},{"nctId":"NCT05222009","phase":"PHASE1","title":"G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-01-24","conditions":"Granulocyte Colony-Stimulating Factor, PD-1 Inhibitor","enrollment":25},{"nctId":"NCT05222035","phase":"PHASE2","title":"PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-01-24","conditions":"PD-1 Inhibitor, G-CSF","enrollment":68},{"nctId":"NCT05156554","phase":"NA","title":"PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-12","conditions":"Lymphoma","enrollment":80},{"nctId":"NCT04547829","phase":"PHASE2","title":"Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-10-10","conditions":"Pediatric Cancer","enrollment":108},{"nctId":"NCT03511378","phase":"PHASE4","title":"Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Lupin Ltd.","startDate":"2018-03-06","conditions":"Breast Cancer","enrollment":138},{"nctId":"NCT04773327","phase":"NA","title":"Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies","status":"UNKNOWN","sponsor":"Xiaohua Wu MD","startDate":"2021-05","conditions":"Gynecologic Malignant Tumor","enrollment":150},{"nctId":"NCT02392793","phase":"PHASE1","title":"Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2015-03-25","conditions":"Childhood Solid Tumors","enrollment":43},{"nctId":"NCT01169636","phase":"PHASE1, PHASE2","title":"Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-01-31","conditions":"Hodgkin's Lymphoma","enrollment":62},{"nctId":"NCT00671658","phase":"PHASE2","title":"Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-11","conditions":"Leukemia, Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT04009941","phase":"PHASE4","title":"Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer","status":"COMPLETED","sponsor":"Peking University","startDate":"2019-08-01","conditions":"Breast Cancer, Neutropenia","enrollment":104},{"nctId":"NCT00101010","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-09","conditions":"Lymphoma","enrollment":80},{"nctId":"NCT01896856","phase":"PHASE1, PHASE2","title":"Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-10-23","conditions":"Previously Treated Metastatic Colorectal Cancer","enrollment":118},{"nctId":"NCT04500886","phase":"NA","title":"Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-08-01","conditions":"Hemophagocytic Syndrome","enrollment":50},{"nctId":"NCT04497688","phase":"NA","title":"Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2019-01-01","conditions":"Non Hodgkin's Lymphoma","enrollment":104},{"nctId":"NCT04497701","phase":"NA","title":"Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-08-01","conditions":"Lymphoma, Leukemia","enrollment":139},{"nctId":"NCT02685111","phase":"PHASE2","title":"Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2016-02","conditions":"Breast Cancer, Neutropenia, Febrile Neutropenia","enrollment":22},{"nctId":"NCT04460079","phase":"","title":"Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2016-03-29","conditions":"Chemotherapy-induced Neutropenia","enrollment":654},{"nctId":"NCT00720109","phase":"PHASE2, PHASE3","title":"Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-14","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":63},{"nctId":"NCT02279134","phase":"PHASE2, PHASE3","title":"Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma","status":"UNKNOWN","sponsor":"Zefen Xiao","startDate":"2014-10","conditions":"Esophageal Neoplasms, Esophageal Cancer","enrollment":360},{"nctId":"NCT01540812","phase":"","title":"Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2012-02","conditions":"Acute Lymphoblastic Leukemia","enrollment":418},{"nctId":"NCT04239001","phase":"NA","title":"Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-02","conditions":"Advanced Pancreatic Cancer","enrollment":20},{"nctId":"NCT04083079","phase":"PHASE4","title":"Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2019-08-01","conditions":"Lymphoma, Non-Hodgkin, Granulocyte Colony-Stimulating Factor, Cost-Benefit Analysis","enrollment":250},{"nctId":"NCT02392039","phase":"EARLY_PHASE1","title":"Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-12-14","conditions":"Lymphoma","enrollment":1},{"nctId":"NCT00807599","phase":"PHASE2","title":"Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-12-10","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT03870412","phase":"NA","title":"Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma Patients","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2019-02-22","conditions":"Elderly Lymphoma Patients","enrollment":485},{"nctId":"NCT03846414","phase":"","title":"Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2019-02-13","conditions":"Chemotherapy-induced Neutropenia, Myelosuppression","enrollment":1500},{"nctId":"NCT03559387","phase":"PHASE2","title":"Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia","status":"TERMINATED","sponsor":"Prolong Pharmaceuticals","startDate":"2017-08-03","conditions":"Chemotherapy-induced Neutropenia","enrollment":9},{"nctId":"NCT02944604","phase":"PHASE4","title":"The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy","status":"COMPLETED","sponsor":"Peking University","startDate":"2016-09-08","conditions":"Breastcancer","enrollment":240},{"nctId":"NCT03776604","phase":"NA","title":"PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2018-12-05","conditions":"Small Cell Lung Cancer, PEG-rhG-CSF","enrollment":61},{"nctId":"NCT03731442","phase":"PHASE3","title":"Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-11-01","conditions":"Esophageal Cancer","enrollment":300},{"nctId":"NCT03740464","phase":"PHASE3","title":"Long-acting G-CSF for Febrile Neutropenia","status":"UNKNOWN","sponsor":"Lei Li","startDate":"2018-11-10","conditions":"Epithelial Ovarian Cancer, Colony Stimulating Factors, Febrile Neutropenia","enrollment":556},{"nctId":"NCT03701841","phase":"","title":"Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis","status":"UNKNOWN","sponsor":"Anhui Provincial Hospital","startDate":"2018-10","conditions":"Chemotherapy-induced Neutropenia","enrollment":1000},{"nctId":"NCT02005458","phase":"PHASE2","title":"Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2013-12","conditions":"Non Small Cell Lung Cancer, Breast Cancer","enrollment":80},{"nctId":"NCT03202927","phase":"PHASE1","title":"Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Adello Biologics, LLC","startDate":"2017-03-25","conditions":"Healthy Volunteers","enrollment":102},{"nctId":"NCT03206229","phase":"PHASE1","title":"Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Adello Biologics, LLC","startDate":"2017-02-13","conditions":"Healthy Volunteers","enrollment":120},{"nctId":"NCT02983097","phase":"PHASE1, PHASE2","title":"Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP","status":"TERMINATED","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","startDate":"2010-11","conditions":"Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°), Mantle Cell Lymphoma (MCL), Blastoid Variant","enrollment":34},{"nctId":"NCT03404752","phase":"PHASE3","title":"Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.","status":"UNKNOWN","sponsor":"Gema Biotech S.A.","startDate":"2015-08","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT00667615","phase":"PHASE1, PHASE2","title":"Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-04","conditions":"Hodgkin's Disease, Lymphoma","enrollment":30},{"nctId":"NCT00098839","phase":"PHASE1, PHASE2","title":"Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-02","conditions":"Recurrent Childhood Acute Lymphoblastic Leukemia","enrollment":134},{"nctId":"NCT01516736","phase":"PHASE3","title":"Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-03","conditions":"Chemotherapy-induced Neutropenia, Breast Cancer","enrollment":308},{"nctId":"NCT03206684","phase":"PHASE4","title":"To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2017-08","conditions":"Cervical Cancer","enrollment":20},{"nctId":"NCT00953420","phase":"PHASE2","title":"Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-11","conditions":"Nasopharyngeal Carcinoma","enrollment":20},{"nctId":"NCT02761460","phase":"PHASE3","title":"The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia","status":"UNKNOWN","sponsor":"wang shusen","startDate":"2016-05-04","conditions":"Breast Cancer","enrollment":338},{"nctId":"NCT00096135","phase":"NA","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-11","conditions":"Leukemia","enrollment":168},{"nctId":"NCT00615901","phase":"NA","title":"Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-01","conditions":"Breast Cancer","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["G-LASTA","DA-3031"],"phase":"marketed","status":"active","brandName":"PEG-G-CSF","genericName":"PEG-G-CSF","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEG-G-CSF is a pegylated granulocyte colony-stimulating factor that stimulates the bone marrow to produce and release neutrophils, reducing the duration and severity of chemotherapy-induced neutropenia. Used for Chemotherapy-induced neutropenia in patients with non-myeloid malignancies, Reduction of duration of severe neutropenia in patients receiving myeloablative chemotherapy followed by bone marrow transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}